crackdown on glp 1 meds GLP-1 compounders find loophole in FDA crackdown, study suggests https://hubs.ly/Q04q4YY_0 FDA to Restrict Ingredients Used

The primary safety concern involves potential degradation products

the incurrence of significant net losses and the fact that the Company expects to continue to incur significant net losses for the foreseeable future

Overview of main clinical studies for MASLD/MASH with GLP-1 receptor agonists and dual or triple agonists targeting glucagon/GIP/GLP-1 receptors Liraglutide Liraglutide, a once-daily GLP-1 receptor agonist with authorized indications for type 2 diabetes and obesity, was evaluated in the LEAN trial (NCT01237119), a phase 2 randomized controlled study enrolling 52 adults with biopsy-proven MASH [22]

Abbasinejad emphasizes movement as medicine. You dont need to become a marathon runner, but incorporating regular physical activity is essential